Using immune scores and radiomics to improve staging in nasopharyngeal carcinoma
Immune Score Based Radiomics in Nasopharyngeal Carcinoma (IMRAN Study)
This study is testing a new way to stage nasopharyngeal cancer by combining immune system scores with imaging data to see if it can give a better understanding of patient outcomes and treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 494 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Zhejiang Cancer Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 5 sites (Wuhan, Hubei and 4 other locations) |
| Trial ID | NCT05126160 on ClinicalTrials.gov |
What this trial studies
This study aims to develop an immune score-based radiomic staging system for nasopharyngeal carcinoma (NPC) to enhance prognostic accuracy. Currently, the TNM staging system is used, but it does not account for the variability in patient outcomes with similar stages. By integrating immune scores with radiomic data, the study seeks to provide a more personalized assessment of prognosis and treatment strategies for NPC patients. The study will involve patients with newly confirmed non-keratinizing or keratinizing carcinoma and will assess their immune profiles alongside imaging data.
Who should consider this trial
Good fit: Ideal candidates include patients with newly histologically confirmed non-keratinizing or keratinizing nasopharyngeal carcinoma and an ECOG performance status of 0-1.
Not a fit: Patients with prior malignancies, severe intercurrent diseases, or those who have undergone previous chemotherapy or radiotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate prognostic assessments and tailored treatment plans for patients with nasopharyngeal carcinoma.
How similar studies have performed: While the specific approach of combining immune scores with radiomics is novel, similar studies have shown promise in improving prognostic models in other cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients with newly histologically confirmed non-keratinizing/keratinizing carcinoma. ECOG Performance status: 0-1 With normal liver function test (ALT, AST ≤2.5ULN) Renal: creatinine clearance ≥60ml/min Without hematopathy,marrow: WBC \>4\*109/L, HGB\>90G/L, and PLT\>100\*109/L. Written informed consent Exclusion Criteria: Contraindications for MRI scan Prior malignancy (except adequately treated carcinoma in-situ of the cervix or · basal/squamous cell carcinoma of the skin) Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume) Patient is pregnant or lactating Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \>1.5×ULN), or emotional disturbance.
Where this trial is running
Wuhan, Hubei and 4 other locations
- Renmin Hospital of Wuhan University — Wuhan, Hubei, China (Recruiting)
- Ningbo First Hospital — Ningbo, Ningbo, China (Recruiting)
- Ningbo Medical Center Lihuili Hospital — Ningbo, Ningbo, China (Recruiting)
- The First Affiliated Hospital of Wenzhou Medical University — Wenzhou, Wenzhou, China (Recruiting)
- Zhejiang Cancer Hospital — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Principal investigator: Xiaozhong Chen — Department of Radiation Oncology, Zhejiang Cancer Hospital
- Study coordinator: Xiaozhong Chen
- Email: cxzfyun@sina.com
- Phone: 0571-88128202
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.